{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:58:59Z","timestamp":1792511939342,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005925","name":"Buddhist Tzu Chi Medical Foundation","doi-asserted-by":"crossref","award":["TCMF-A 107-01-07(112)"],"award-info":[{"award-number":["TCMF-A 107-01-07(112)"]}],"id":[{"id":"10.13039\/501100005925","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005925","name":"Buddhist Tzu Chi Medical Foundation","doi-asserted-by":"crossref","award":["TCMF-A 107-01-07(112)"],"award-info":[{"award-number":["TCMF-A 107-01-07(112)"]}],"id":[{"id":"10.13039\/501100005925","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005925","name":"Buddhist Tzu Chi Medical Foundation","doi-asserted-by":"crossref","award":["TCMF-A 107-01-07(112)"],"award-info":[{"award-number":["TCMF-A 107-01-07(112)"]}],"id":[{"id":"10.13039\/501100005925","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005925","name":"Buddhist Tzu Chi Medical Foundation","doi-asserted-by":"crossref","award":["TCMF-A 107-01-07(112)"],"award-info":[{"award-number":["TCMF-A 107-01-07(112)"]}],"id":[{"id":"10.13039\/501100005925","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005925","name":"Buddhist Tzu Chi Medical Foundation","doi-asserted-by":"crossref","award":["TCMF-A 107-01-07(112)"],"award-info":[{"award-number":["TCMF-A 107-01-07(112)"]}],"id":[{"id":"10.13039\/501100005925","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005925","name":"Buddhist Tzu Chi Medical Foundation","doi-asserted-by":"crossref","award":["TCMF-A 107-01-07(112)"],"award-info":[{"award-number":["TCMF-A 107-01-07(112)"]}],"id":[{"id":"10.13039\/501100005925","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005925","name":"Buddhist Tzu Chi Medical Foundation","doi-asserted-by":"crossref","award":["TCMF-A 107-01-07(112)"],"award-info":[{"award-number":["TCMF-A 107-01-07(112)"]}],"id":[{"id":"10.13039\/501100005925","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Teriparatide, a recombinant parathyroid hormone, is pivotal in osteoporosis treatment, particularly in post-surgical recovery for hip fractures. This study investigates its efficacy in functional recovery post-hip fracture surgery in elderly patients, a demographic particularly susceptible to osteoporotic fractures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective cohort study, 150 elderly patients with proximal femoral fractures undergoing open reduction and internal fixation were enrolled. They were categorized into two groups: receiving 20\u00a0\u00b5g of daily teriparatide injections for 18 months and receiving standard antiresorptive medications during a 24-month follow-up. Detailed records of patient demographics, Fracture Risk Assessment Tool scores, and comorbidities were kept. Key outcomes, including bone mineral density (BMD) and functional scores (Barthel Index and Visual Analog Scale for hip pain), were evaluated at 3 and 24 months post-surgery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Out of the original cohort, 126 patients (20 men and 106 women with an average age of 85.5\u2009\u00b1\u20099.3 years) completed the study. The teriparatide group exhibited significant enhancements in both functional scores and BMD when compared to the control group. Notably, functional improvements were less pronounced in male patients compared to female patients. Additionally, the incidence of new fractures was markedly lower in the teriparatide group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Administering teriparatide daily for 18 months post-surgery for proximal femoral fractures significantly benefits very elderly patients by improving functionality and bone density, with observed differences in recovery between genders. These results reinforce the efficacy of teriparatide as a potent option for treating osteoporosis-related fractures in the elderly and highlight the importance of considering gender-specific treatment and rehabilitation strategies.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12891-024-07373-6","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T04:01:28Z","timestamp":1712980888000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic advantage of teriparatide in very elderly patients with proximal femoral fractures: a functional and BMD analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Ooi Chin","family":"Sheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Tien","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Huan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Kuo","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ing-Ho","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Hung","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Ting","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,13]]},"reference":[{"key":"7373_CR1","doi-asserted-by":"publisher","unstructured":"Bledsoe L, Alessi K, Toro JB, Giordano B, Hanypsiak BT. Fragility fractures: diagnosis and treatment. Am J Orthop (Belle Mead NJ). 2018;47(12). https:\/\/doi.org\/10.12788\/ajo.2018.0112","DOI":"10.12788\/ajo.2018.0112"},{"key":"7373_CR2","doi-asserted-by":"publisher","first-page":"1297950","DOI":"10.3389\/fendo.2023.1297950","volume":"14","author":"A Galvano","year":"2023","unstructured":"Galvano A, Gristina V, Scaturro D, Bazan Russo TD, Tomasello S, Vitagliani F, et al. The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors. Front Endocrinol (Lausanne). 2023;14:1297950.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"7373_CR3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.5312\/wjo.v7.i3.171","volume":"7","author":"P Pisani","year":"2016","unstructured":"Pisani P, Renna MD, Conversano F, Casciaro E, Di Paola M, Quarta E, et al. Major osteoporotic fragility fractures: risk factor updates and societal impact. World J Orthop. 2016;7:171\u201381.","journal-title":"World J Orthop"},{"issue":"3 Suppl","key":"7373_CR4","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1097\/OI9.0000000000000178","volume":"5","author":"LGP Rojas","year":"2022","unstructured":"Rojas LGP, Cervantes REL, Almejo LL, Pesciallo CA, Garabano G, Bidolegui F, et al. Fragility fracture systems, Latin America perspective. OTA Int. 2022;5(3 Suppl):e178.","journal-title":"OTA Int"},{"key":"7373_CR5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.21037\/aoj.2019.01.01","volume":"4","author":"CF van Eck","year":"2019","unstructured":"van Eck CF, Klein CM, Rahmi H, Scheidt KB, Schultzel M, Lee BK, et al. Morbidity, mortality and cost of osteoporotic fractures\u2014should proximal humerus fractures be taken as seriously as hip fractures? Ann Joint. 2019;4:3.","journal-title":"Ann Joint"},{"key":"7373_CR6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1136\/annrheumdis-2017-212475","volume":"77","author":"F Aguiar","year":"2018","unstructured":"Aguiar F, Guerra M, Ganh\u00e3o S, Gon\u00e7alves D, Martins-Rocha T, Fereira RM, et al. THU0485\u2005Predicting 1-year mortality after a fragility hip fracture \u2013 the experience of a fracture liaison service. Anna Rheum Dis. 2018;77:450\u20131.","journal-title":"Anna Rheum Dis"},{"key":"7373_CR7","doi-asserted-by":"publisher","first-page":"1759720X1987799","DOI":"10.1177\/1759720X19877994","volume":"11","author":"S Minisola","year":"2019","unstructured":"Minisola S, Cipriani C, Grotta GD, Colangelo L, Occhiuto M, Biondi P, et al. Update on the safety and efficacy of teriparatide in the treatment of osteoporosis. Ther Adv Musculoskelet Dis. 2019;11:1759720X19877994.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"7373_CR8","doi-asserted-by":"crossref","first-page":"300060519876744","DOI":"10.1177\/0300060519876744","volume":"48","author":"T Yang","year":"2020","unstructured":"Yang T, Feng C, Qu Y, Wang Q, Yang Y, Wang B, et al. Effect of teriparatide on quality of life in patients with postmenopausal osteoporosis: a retrospective cohort study. J Int Med Res. 2020;48:300060519876744.","journal-title":"J Int Med Res"},{"key":"7373_CR9","doi-asserted-by":"publisher","first-page":"e66532","DOI":"10.7554\/eLife.66532","volume":"10","author":"Q Sun","year":"2021","unstructured":"Sun Q, Zhen G, Li TP, Guo Q, Li Y, Su W, et al. Parathyroid hormone attenuates osteoarthritis pain by remodeling subchondral bone in mice. Elife. 2021;10:e66532.","journal-title":"Elife"},{"key":"7373_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/1759720X09339551","volume":"1","author":"M Mulgund","year":"2009","unstructured":"Mulgund M, Beattie KA, Wong AK, Papaioannou A, Adachi JD. Assessing adherence to teriparatide therapy, causes of nonadherence and effect of adherence on bone mineral density measurements in osteoporotic patients at high risk for fracture. Ther Adv Musculoskelet Dis. 2009;1:5\u201311.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"7373_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jcot.2012.04.001","volume":"3","author":"R Mittal","year":"2012","unstructured":"Mittal R, Banerjee S. Proximal femoral fractures: principles of management and review of literature. J Clin Orthop Trauma. 2012;3:15\u201323.","journal-title":"J Clin Orthop Trauma"},{"key":"7373_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.4103\/2230-8210.95661","volume":"16","author":"ML Cheng","year":"2012","unstructured":"Cheng ML, Gupta V. Teriparatide - indications beyond osteoporosis. Indian J Endocrinol Metab. 2012;16:343\u20138.","journal-title":"Indian J Endocrinol Metab"},{"key":"7373_CR13","first-page":"61","volume":"14","author":"MAHONEY FI, BARTHEL DW","year":"1965","unstructured":"MAHONEY FI, BARTHEL DW. FUNCTIONAL EVALUATION: THE BARTHEL INDEX. Md. State Med J. 1965;14:61\u20135.","journal-title":"State Med J"},{"key":"7373_CR14","first-page":"e37676","volume":"15","author":"S Koudouna","year":"2023","unstructured":"Koudouna S, Evangelopoulos DS, Sarantis M, Chronopoulos E, Dontas IA, Pneumaticos S. The Effect of Postoperative Physical Therapy following hip fracture: a Literature Review. Cureus. 2023;15:e37676.","journal-title":"Cureus"},{"key":"7373_CR15","doi-asserted-by":"publisher","first-page":"1759720X2211334","DOI":"10.1177\/1759720X221133429","volume":"14","author":"G Iolascon","year":"2022","unstructured":"Iolascon G, Paoletta M, Liguori S, Gimigliano F, Moretti A. Bone fragility: conceptual framework, therapeutic implications, and COVID-19-related issues. Ther Adv Musculoskelet Dis. 2022;14:1759720X221133429.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"7373_CR16","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/jbmr.3972","volume":"35","author":"P Chotiyarnwong","year":"2020","unstructured":"Chotiyarnwong P, McCloskey E, Eastell R, McClung MR, Gielen E, Gostage J, et al. A pooled analysis of fall incidence from placebo-controlled trials of Denosumab. J Bone Min Res. 2020;35:1014\u201321.","journal-title":"J Bone Min Res"},{"key":"7373_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/jfmk6010024","volume":"6","author":"D Scaturro","year":"2021","unstructured":"Scaturro D, Rizzo S, Sanfilippo V, Giustino V, Messina G, Martines F, et al. Effectiveness of rehabilitative intervention on Pain, Postural Balance, and quality of life in women with multiple vertebral fragility fractures: a prospective cohort study. J Funct Morphol Kinesiol. 2021;6:24.","journal-title":"J Funct Morphol Kinesiol"},{"key":"7373_CR18","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1210\/jc.2015-4181","volume":"101","author":"DW Dempster","year":"2016","unstructured":"Dempster DW, Zhou H, Recker RR, Brown JP, Recknor CP, Lewiecki EM, et al. Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA osteoporosis study. J Clin Endocrinol Metab. 2016;101:1353\u201363.","journal-title":"J Clin Endocrinol Metab"},{"key":"7373_CR19","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1359\/jbmr.090416","volume":"24","author":"C Graeff","year":"2009","unstructured":"Graeff C, Chevalier Y, Charlebois M, Varga P, Pahr D, Nickelsen TN, et al. Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study. J Bone Min Res. 2009;24:1672\u201380.","journal-title":"J Bone Min Res"},{"key":"7373_CR20","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","volume":"164","author":"R Lindsay","year":"2004","unstructured":"Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004;164:2024\u201330.","journal-title":"Arch Intern Med"},{"key":"7373_CR21","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/jbmr.3067","volume":"32","author":"J Malouf-Sierra","year":"2017","unstructured":"Malouf-Sierra J, Tarantino U, Garc\u00eda-Hern\u00e1ndez PA, Corradini C, Overgaard S, Stepan JJ, et al. Effect of teriparatide or Risedronate in Elderly patients with a recent pertrochanteric hip fracture: final results of a 78-Week randomized clinical trial. J Bone Min Res. 2017;32:1040\u201351.","journal-title":"J Bone Min Res"},{"key":"7373_CR22","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391:230\u201340.","journal-title":"Lancet"},{"key":"7373_CR23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s00223-021-00895-4","volume":"110","author":"CH Chen","year":"2022","unstructured":"Chen CH, Elsalmawy AH, Ish-Shalom S, Lim SJ, AlAli NS, Cunha-Borges JL, et al. The Effect of Teriparatide Treatment on the risk of Fragility fractures in Postmenopausal Women with osteoporosis: results from the Asian and Latin America Fracture Observational Study (ALAFOS). Calcif Tissue Int. 2022;110:74\u201386.","journal-title":"Calcif Tissue Int"},{"key":"7373_CR24","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.injury.2019.06.002","volume":"50","author":"SJ Kim","year":"2019","unstructured":"Kim SJ, Park HS, Lee DW, Lee JW. Short-term daily teriparatide improve postoperative functional outcome and fracture healing in unstable intertrochanteric fractures. Injury. 2019;50:1364\u201370.","journal-title":"Injury"},{"key":"7373_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2378","author":"TC Wu","year":"2023","unstructured":"Wu TC, Tsou YJ, Wu WT, Lee RP, Wang JH, Yeh KT. Five-year outcomes of continuous treatment with Zoledronic Acid Versus Denosumab in older men with high fracture risk: risk factor analysis of bone density improvement and incidence of New Fracture. J Clin Pharmacol. 2023. https:\/\/doi.org\/10.1002\/jcph.2378. Online ahead of print.","journal-title":"J Clin Pharmacol"},{"key":"7373_CR26","doi-asserted-by":"publisher","first-page":"818","DOI":"10.7326\/M15-1361","volume":"166","author":"A Qaseem","year":"2017","unstructured":"Qaseem A, Forciea MA, McLean RM, Denberg TD, Clinical Guidelines Committee of the American College of Physicians, Barry MJ, et al. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice Guideline Update from the American College of Physicians. Ann Intern Med. 2017;166:818\u201339.","journal-title":"Ann Intern Med"},{"key":"7373_CR27","doi-asserted-by":"publisher","first-page":"155798831985673","DOI":"10.1177\/1557988319856739","volume":"13","author":"JR Novak","year":"2019","unstructured":"Novak JR, Peak T, Gast J, Arnell M. Associations between masculine norms and health-care utilization in highly religious, heterosexual men. Am J Mens Health. 2019;13:1557988319856739.","journal-title":"Am J Mens Health"},{"key":"7373_CR28","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1177\/1559827618812395","volume":"13","author":"JM Rippe","year":"2018","unstructured":"Rippe JM. Lifestyle strategies for risk factor reduction, Prevention, and treatment of Cardiovascular Disease. Am J Lifestyle Med. 2018;13:204\u201312.","journal-title":"Am J Lifestyle Med"},{"key":"7373_CR29","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1007\/s00198-010-1498-5","volume":"22","author":"A Fahrleitner-Pammer","year":"2011","unstructured":"Fahrleitner-Pammer A, Langdahl BL, Marin F, Jakob F, Karras D, Barrett A, et al. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos Int. 2011;22:2709\u201319.","journal-title":"Osteoporos Int"},{"key":"7373_CR30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00223-018-0485-2","volume":"104","author":"S Silverman","year":"2019","unstructured":"Silverman S, Langdahl BL, Fujiwara S, Saag K, Napoli N, Soen S, et al. Reduction of hip and other fractures in patients receiving teriparatide in real-world clinical practice: Integrated Analysis of four prospective observational studies. Calcif Tissue Int. 2019;104:193\u2013200.","journal-title":"Calcif Tissue Int"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-024-07373-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12891-024-07373-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-024-07373-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T05:31:07Z","timestamp":1731735067000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-024-07373-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,13]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["7373"],"URL":"https:\/\/doi.org\/10.1186\/s12891-024-07373-6","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,13]]},"assertion":[{"value":"9 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation (IRB108-92-B). This study has confirmed that all the experiments were performed in accordance with relevant guidelines and regulations. The informed consent have all been obtained from the study participants prior to the study commencement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicting interests"}}],"article-number":"288"}}